Burzynski Clinic Presents the Successful Treatment of a Child with Recurrent Diffuse Intrinsic Pontine Gliosarcoma at the Congress
HOUSTON, Nov. 26, 2013 /PRNewswire/ — The Burzynski Clinic (BC) announced today the successful treatment of a child with recurrent diffuse intrinsic pontine gliosarcoma (DIPGGS) at the 4(th) Quadrennial Meeting of the World Federation of Neuro-Oncology in San Francisco. Pediatric gliosarcoma (GS) is a rare variant of glioblastoma multiforme. The pontine location of this tumor is unusual, invariably fatal and successful treatment was not yet described in medical literature. The poster presentation at the congress described the case of a 9-year-old boy who was initially diagnosed with low-grade astrocytoma (LGA) that was successfully controlled for four years, but subsequently his brain tumor transformed into a DIPGGS. Prior treatment of his LGA included tumor resection three times, standard radiation therapy, and Gamma Knife procedure twice. His LGA was also treated with standard chemotherapy and his GS with subtotal resection, high-dose chemotherapy with stem cell rescue followed by regular chemotherapy. Unfortunately, he developed a disseminated disease with multiple tumors and leptomeningeal involvement including a tumor occupying 80% of the pons. He received treatment with antineoplastons A10 and AS2-1 (ANP) under compassionate exception to phase II protocol BT-22 of the clinic. The patient response was evaluated by magnetic resonance imaging (MRI) and positron emission tomography (PET). The patient achieved a complete response and improvement in his condition and he is currently disease-free for over 13 years from the treatment start. He experienced only one type of grade 4 toxicity, which was reversible hypernatremia. His pathology diagnosis was confirmed by external neuropathologists and his response to treatment was determined by Central Radiology Review.
In conclusion, this report indicates that it is possible to obtain long-term survival of a child with highly aggressive recurrent GS with diffuse pontine involvement with a currently available investigational treatment.
Forward-looking statements in this release are made pursuant to the safe harbor provisions of the federal securities laws. Information contained in forward-looking statements is based on current expectations and is subject to change, and future events may differ materially from those discussed herein due to a number of factors, including, but not limited to, risks and uncertainties related to the clinic’s ability to use personalized targeted cancer therapy. Burzynski Clinic does not undertake to update any such forward-looking statements or to publicly announce developments or events relating to the matters described herein.
SOURCE Burzynski Clinic